Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-04 · accession 0001576885-25-000082 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-05 | 2025-06-04 | ABOS | Stalfort John A III | Dir | A - Grant | $0.00 | +12.8K | 185.1K | +7% | $0 |
| D | 2025-06-05 | 2025-06-04 | ABOS | Stalfort John A III | Dir | A - Grant | $0.00 | +19.5K | 19.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-04 | A | A | 12,800 | $0.00 | 185,124 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-06-04 | A | A | 19,500 | $0.00 | 19,500 | D | $1.07 · — to 2035-06-04 | 19,500 Common Stock | (F2) The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |